Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future

被引：14

作者：

Desai, Anjali Varma ^{[1
]}

El-Bakkar, Hassan ^{[1
]}

Abdul-Hay, Maher ^{[1
]}

机构：

[1] NYU, Langone Med Ctr, Inst Canc, Div Hematol & Med Oncol, New York, NY 10016 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2015年 / 15卷 / 06期

关键词：

B cell lymphoma 2 inhibitors; Bruton tyrosine kinase inhibitors; CDK inhibitors; Immunomodulators; PI3K inhibitors; DEPENDENT KINASE INHIBITOR; BRUTONS TYROSINE KINASE; PHASE-II TRIAL; T-CELLS; B-CELLS; UNTREATED PATIENTS; INITIAL THERAPY; RITUXIMAB; LENALIDOMIDE; FLUDARABINE;

D O I：

10.1016/j.clml.2014.09.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Half of a century ago, physicians managing chronic lymphocytic leukemia (CLL) recognized some of its presenting features such as lymphocytosis, lymphadenopathy, and splenomegaly. Subsequently, an enhanced understanding of the disease mechanisms involved in CLL led to new, more targeted treatments. There is now a plethora of treatments available for CLL. In this review article we discuss in detail several of the novel agents that are being studied or approved for the treatment of CLL including: phosphatidylinositol 3-kinase inhibitors (idelalisib and IPI-145), Bruton tyrosine kinase inhibitors (ibrutinib), B cell lymphoma 2 inhibitors (ABT-263 and ABT-199), new anti-CD20 monoclonal antibodies (obinutuzumab), cyclin-dependent kinase inhibitors (flavopiridol and dinaciclib), immunomodulators (lenalidomide) and chimeric antigen receptor T-cell therapy.

引用

页码：314 / 322

页数：9

共 64 条

[1]

[Anonymous], SEER STAT FACT SHEET

[2]

[Anonymous], ASCO M ABSTR S

[3] Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia [J].

Badoux, Xavier C. ;

Keating, Michael J. ;

Wen, Sijin ;

Lee, Bang-Ning ;

Sivina, Mariela ;

Reuben, James ;

Wierda, William G. ;

O'Brien, Susan M. ;

Faderl, Stefan ;

Kornblau, Steven M. ;

Burger, Jan A. ;

Ferrajoli, Alessandra .

BLOOD, 2011, 118 (13) :3489-3498

[4]

BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO

[5]

2-V

[6] Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias [J].

Brentjens, Renier J. ;

Riviere, Isabelle ;

Park, Jae H. ;

Davila, Marco L. ;

Wang, Xiuyan ;

Stefanski, Jolanta ;

Taylor, Clare ;

Yeh, Raymond ;

Bartido, Shirley ;

Borquez-Ojeda, Oriana ;

Olszewska, Malgorzata ;

Bernal, Yvette ;

Pegram, Hollie ;

Przybylowski, Mark ;

Hollyman, Daniel ;

Usachenko, Yelena ;

Pirraglia, Domenick ;

Hosey, James ;

Santos, Elmer ;

Halton, Elizabeth ;

Maslak, Peter ;

Scheinberg, David ;

Jurcic, Joseph ;

Heaney, Mark ;

Heller, Glenn ;

Frattini, Mark ;

Sadelain, Michel .

BLOOD, 2011, 118 (18) :4817-4828

[7] Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells [J].

Burger, JA ;

Burger, M ;

Kipps, TJ .

BLOOD, 1999, 94 (11) :3658-3667

[8] High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation [J].

Burger, Jan A. ;

Quiroga, Maite P. ;

Hartmann, Elena ;

Buerkle, Andrea ;

Wierda, William G. ;

Keating, Michael J. ;

Rosenwald, Andreas .

BLOOD, 2009, 113 (13) :3050-3058

[9] Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712) [J].

Byrd, JC ;

Peterson, BL ;

Morrison, VA ;

Park, K ;

Jacobson, R ;

Hoke, E ;

Vardiman, JW ;

Rai, K ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2003, 101 (01) :6-14

[10] Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011 [J].

Byrd, JC ;

Rai, K ;

Peterson, BL ;

Appelbaum, FR ;

Morrison, VA ;

Kolitz, JE ;

Shepherd, L ;

Hines, JD ;

Schiffer, CA ;

Larson, RA .

BLOOD, 2005, 105 (01) :49-53

← 1 2 3 4 5 6 7 →